• Massive opportunity ahead says CEO of Autonomous Security Robot maker Knightscope
• Wide ranging interview discloses vast potential in federal applications
• Knightscope’s state of the art ASRs provide cost effective 24/7/365 security

The rise of machines has arrived. Relax, it isn’t the rise of Skynet, the malevolent neural network superintelligence system from the movie Terminator. This rise of machines has no malice. In fact, these machines benefit society by uniquely combining robotics, self-driving technology, and artificial intelligence to reduce crime as well as provide safety, security, and real-time data in a multitude of settings. With the rise of its Autonomous Security Robots (“ASRs”), tech innovator Knightscope is on track to revolutionize the $500 billion security industry. The company is rapidly displacing moribund security duties across the country and its ASRs are already on-guard in federal government facilities, public institutions, and numerous Fortune 1000 companies. Knightscope’s ASRs operate 24/7/365 providing real-time access to data around the clock and can capture 90 terabytes of data each year. These machines also feature 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. Not only does the presence of ASRs help deter crime, but these sentries also help law enforcement reaction times, provide resolution to any legal matters with recorded video as well as provide training and operational improvement opportunities. On top of all the technological wizardry, Knightscope’s ASRs save customers money by cost effectively augmenting the high costs of security. The future looks bright for Knightscope. In a recent IPO Edge Fireside Chat with Knightscope CEO William Santana Li was quite bullish on the outlook. He sees a massive opportunity ahead, especially with the federal government. In the interview he stated, “The federal government is going to be, I think, a long term very very large client for us.” As Mr. Li outlined, just think of all the federal applications that need augmented 24/7/365 security. Military bases and their storage facilities, national parks, FEMA warehouses, Federal courthouses – the list of applications is seemingly endless, and the company is on a roll. Knightscope has brought the future to the present with its innovation and market disrupting technology. The company is rapidly gaining traction, deploying its sentries to public and private entities, saving customers money, and providing improved security across the country. There’s certainly nothing to fear from this rise of machines. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Ideanomics, Inc. (NASDAQ: IDEX) recently entered into an investment agreement promising to purchase over 6 million Energica ordinary shares using a subscribed-shares arrangement that priced each subscribed share at Euro 1.78
• In total, IDEX would invest approximately 13 million dollars in the Italy-based manufacturer of all-electric high-performance motorcycles
• According to IDEX CEO Alf Poor, the investment was driven by Energica’s manufacture of high-performance products that produce zero emissions
• In 2020, Energica experienced a 187% increase in revenue compared to 2019, and there is high demand for Energica’s motorcycles in the U.S.

Ideanomics (NASDAQ: IDEX), a global company focused on investing in and promoting innovative solutions in the financial and electric vehicle (“E.V.”) spaces, recently entered into an investment agreement with Energica Motor Company S.p.A. (“Energica”), an Italian listed electric motorcycle company, that will see it acquire at least 20% of Energica, upon completion of the requisite transactions. According to a March 4 announcement issued by Energica, IDEX promised to purchase 64% of the share capital increase, the equivalent of 6,128,703 Energica ordinary shares, in a subscribed-shares arrangement. Notably, subscribed shares are shares that investors promise to buy as part of an initial public offering or a share capital increase (https://ibn.fm/H10Ca). Under the agreement, IDEX would pay a subscription price of Euro 1.78 per share, arrived at by calculating the weighted average of the official price of Energica shares over the six months prior to the execution of the transaction, bringing IDEX’s total subscribed share capital to Euro 10,909,091. The transaction would be settled in the few days following the publication of the announcement. Once completed, the transaction will bring the total number of Ideanomics’ wholly-owned businesses and companies wherein it is a direct investor in the EV space to 7 (https://ibn.fm/TzfpG). The latest investment, Energica, will be part of Ideanomics’ Mobility division and is the second of its kind for IDEX, which acquired a controlling stake in Treeletrik’s sales and distribution arm in March 2019. At the time, Treeletrik, which manufactures all-electric bikes, was the only licensed EV manufacturer in Malaysia. Therefore, the investment in Energica looks like a calculated strategy in Ideanomics’ quest for a wholesome portfolio that includes every category of E.V.s, namely buses, vans, cars, trucks, and motorcycles, also allowing battery technology synergies to play out between Energica and Treeletik Energica, the first Italian manufacturer of high-performance electric motorcycles, has posted growth in its revenue and order backlog year-on-year. According to its preliminary 2020 turnover report, the manufacturer posted Euro 6 million in revenue, constituting a 187% increase from the figure reported at a similar period in 2019 (https://ibn.fm/ARZNJ), despite the vagaries brought by the pandemic. “Energica has combined zero emission E.V. technology with the pedigree of high-performance mobility synonymous with Italy’s Motor Valley to create a range of exceptional products for the high-performance motorcycle market,” Alf Poor, CEO of Ideanomics, said of the company. “We were very impressed with Livia (Energica’s CEO) and her team throughout our discussion, and we are very pleased to support them through their next phase of growth.” In the first two months of the 2021 fiscal year – starting December 2020 – Energica had already received new orders valued at over Euro 2.9 million and equivalent to 49.7% of the orders it received throughout 2020. 30% of these orders were from the United States. Moreover, the U.S. orders received between March 25 and April 28 accounted for 41% of the total. These figures signal that Ideanomics’ investment in the motorcycle manufacturer could also be due to the increasing popularity of Energica’s motorcycles in the North American market. On her part, Livia Cevolini voiced her pride in being part of a unified platform that shared the same vision. “The creation of a network of innovative companies can only accelerate the growth and adoption of new technologies such as sustainable mobility that sees us among the leaders,” she continued. “The investment will give further strength to the Energica growth already underway in recent years thanks to the innovation brought to our products with the racing experience in MotoE.” The investment brings Ideanomics closer to realizing its vision to build advanced technology ecosystems that deliver more efficient and environmentally-friendly solutions to the world. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Canada House subsidiary Abba Medix to distribute Pure Extract line of full spectrum oil vape and edible products throughout its nationwide network
• Partnership widens Pure Extracts’ footprint in Canada’s growing Cannabis 2.0 market
• Global extraction product market expected to reach $28.5 billion in next six years
• New agreement strengthens Pure Extracts’ sales channels as it looks towards international expansion

There’s plenty of media coverage about increasing legalization of cannabis for medical and adult recreational use driving a broad market expected to reach $73.6 billion by 2027 (https://ibn.fm/ICOlM), but not as much about the cannabis extraction market that is growing at nearly the same annual clip (18.1% vs. 16.6%, respectively) to reach $28.5 billion at the same time (https://ibn.fm/jPkyu). Perhaps it is because people can easily grasp the top-level idea of smoking cannabis buds, while the idea of processing cannabis and hemp into tinctures, oils, vapes, edibles and other products like Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) does is far more complex. It’s arguable, though, that buds, excluding high-end crafts and medical grade, are a bit of a race to the bottom with pricing while extraction products seem sexier with their diversity of applications and higher margins.

The onset of Cannabis 2.0, the colloquial name for regulatory changes late in 2019 that legalized marijuana derivative products in Canada, paved the way for a spate of new products to hit retailer shelves in 2020, but the momentum has been a slow build that is now accelerating. Data from Statistics Canada shows that 527,987 units of adult-use extract products were bought in Canada in January 2020, a figure that swelled to 1.33 million units in October 2020 (https://ibn.fm/OrgQL). Increased awareness as to the bevy of benefits of cannabis compounds amongst consumers and patients is expected to drive market growth going forward, according Data Bridge Market Research, which predicts a 21.0% CAGR to 2027 for the extract market (https://ibn.fm/EDfDt).

As consumer uptake grows, Pure Extracts is positioning to widen its Canadian footprint for its lineup of Cannabis 2.0 products. On Friday, the Vancouver-based company said it partnered with integrated medical cannabis company Canada House Wellness Group (CSE: CHV). Per the pact, Canada House’s Abba Medix Corp. unit will distribute Pure Extracts’ line of concentrate products through its established provincial distribution channels.

Pure Extracts CEO Ben Nikolaevsky sees the new partnership as a quick and efficient way to get the Company’s line of full spectrum oil vape and edible products to retail buyers across Canada while their Sales Amendment application is being processed by Health Canada.

“We’ve been extremely impressed with the Pure Extracts team and the brand presence they have established, particularly in the western provinces, and are looking forward to supporting their commercialization efforts in a mutually beneficial way,” commented Canada House CEO Chris Churchill (https://ibn.fm/WHVZC).

Pure Extracts operates a 10,000 square foot state-of-the-art processing facility situated 20 minutes north of Whistler, British Columbia. The new facility was purpose built to European GMP (good manufacturing practices) standards as Pure Extracts looks ahead towards export sales of products and formulations, which include not only cannabis, but hemp biomass, and functional and psychedelic mushroom products as well.

Already possessing a Standard Processing License by Health Canada under the Cannabis Act, Pure Extracts is aligning for additional licenses and certifications that will facilitate exporting a diverse product line. These are expected to include even products restricted in Canada at this time, but legally available in countries internationally.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical has developed a technology, currently entering the manufacturing stage, which it believes will revolutionize bladder cancer surgical imaging
• The company’s technology, the i/Blue Imaging System, can display blue and white light images of the bladder side-by-side simultaneously, allowing surgeons greater ability to detect and remove tumors
• Imagin has raised a $2.165 million convertible note offering to fund the company during the manufacturing phase of its surgical imaging system as well as the U.S. Food and Drug Administration (“FDA”) approval process
• Bladder cancer is one of the most prevalent cancers in the United States, particularly in men, and is expected to result in the deaths of roughly 17,200 patients this year — approximately 71 percent of them men

The American Cancer Society forecasts that in 2021 about 83,730 new cases of bladder cancer will be diagnosed in the United States, about 77 percent of them in men. And that about 17,200 bladder cancer cases will result in death, about 71 percent of them in men (https://ibn.fm/6NEqE). While bladder cancer rates have been declining for the past decade, the ACS predicts there will be a 3 percent increase this year (https://ibn.fm/8KYwX).

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is preparing to commercialize its proprietary i/Blue Imaging(TM) System once final U.S. Food and Drug Administration (“FDA”) approval has been granted. The purpose-built mission of the i/Blue Imaging System is to bring about a marked improvement in bladder cancer detection through cystoscopy (using conventional endoscopes inside the body to help surgeons detect and resect tumors) and thereby help reduce the incidence of recurrence or severe progression of such cancers.

While cystoscopy has wide use in resecting bladder cancers, it has largely relied on normal visual range white light for illuminating the bladder on surgeons’ video screens despite technological advances by industry suppliers and researchers who have determined blue light and a pink staining dye can help surgeons more effectively locate tumors for resection and remove them more completely.

“Here is the crux of the problem urology has long faced: cystoscopy is the standard of care for diagnosing bladder cancer, but cystoscopy relied upon incident white light from the instrument. White light misses 50% of malignant bladder lesions,” a physician who serves as editor-in-chief of investment media outlet BioPub states in a recent opinion article that touts Imagin’s efforts (https://ibn.fm/okNai). “‘Houston we have a problem:’ when your standard of care is that compromised, you can see how bladder cancer would cultivate a reputation for being hard to cure. Imagin, a small Canadian biotech, has been working behind the scenes with genuine thought leaders in urology to improve diagnostic yield at cystoscopy, and now seems to have done so.”

Imagin is a company “where, when you think about the methodology they’re promulgating, you’re like, it’s so obvious in retrospect,” the physician, known as Dr. KSS, says in an episode of his webcast (https://ibn.fm/3h9Q0). “How did it take medicine so many decades to get to this point? … (The i/Blue Imaging System) is a system that we think will become state of the art, that operators will be really impelled to install lest they not be with standard of care.”

A report by Urology Times described cost benefits from using blue light cystoscopy procedures, stating that in the initial transurethral resection of bladder tumors the procedures “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone” and led to a lower overall burden for patients (https://ibn.fm/COXAr).

One reason Imagin cites for blue light cystoscopy being underutilized is that surgical centers already have an inventory of conventional endoscopes that use white light. Current blue light technology requires the purchase of new customized endoscopes that are only available from one manufacturer, not only adding cost but also rendering the current inventory useless.  In addition, blue light cystoscopy still requires white light images in order to operate, so surgeons need to switch back and forth between the white and blue light images during the procedure to get the full picture of the cancer in the bladder.

Imagin’s i/Blue Imaging System advances existing technologies by using a dualview camera technology that controls images on the monitor and that can be adapted to almost any existing endoscopic equipment surgical centers already own. The i/Blue system can display both blue light images and white light images side-by-side simultaneously during the procedure, eliminating the challenges of comparing blue and white light images by toggling back and forth.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Head CTs, MRIs are most-used but not most-effective tool for head trauma or neurological issues in triage
• EEG changed clinical management of 76.2% of patients, even when CT or MRI was available
• Brain Scientific has overcome key barriers causing EEG underuse in emergency medicine

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is making EEGs accessible in emergency departments (“ED”) with cutting-edge tech that bridges the widening gap in access to quality care. As the public becomes more aware of head trauma’s long-term effects, triages fill up with potential TBIs and acute neurological conditions. Facilities are scrambling to adapt to the growing need but are often ill equipped to do so.

When a patient arrives presenting head trauma or neurological issues, almost reflexively, a head CT and/or MRI is ordered. A BRSF white paper titled “Electroencephalography in the Emergency Department” explains why this is not always the most effective diagnostic tool (https://ibn.fm/IWTxt).

The report notes that head CT is not always the optimal scan for all acute neurological conditions; however, due to its availability, it is overused. Around 70 million CT examinations are performed in EDs annually in the United States (https://ibn.fm/gwcGo). While these are ideal for brain hemorrhage, skull fractures, malignancy and a handful of other conditions, they have been found ineffective at identifying mild traumatic brain injury (“mTBI”) and nontraumatic causes of neurologic dysfunction such as syncope, delirium, and vertigo. The MRI provides higher resolution images and greater detail of the brain than the CT but is limited as a primary diagnostic tool in the ED.

According to the CDC, an estimated 2.5 million TBI-related visits are made to the ED in the U.S. a year (https://ibn.fm/cppKg). Part of the increase is due to the public’s growing knowledge of TBI effects. Neither the head CT or MRI are equipped to diagnose mTBI adequately. The best indicator is an EEG, which can determine the severity of the injury.

Delirium is also often seen in the ED and can affect up to one-half of older patients in hospitals. However, experiencing delirium in a hospital setting does not mean a patient has Alzheimer’s or another dementia diagnosis. Dementia is chronic, while delirium is usually reversible. Determining what the patient is experiencing is essential in creating a successful care plan. An EEG can make this distinction.

The American Academy of Neurology published a study on routine EEGs in emergency room and inpatient services. It was found that the use of the EEG changed the clinical management of 76.2% of patients, even when a normal CT or MRI was available (https://ibn.fm/gCNV4).

Beyond TBIs and dementia, EEGs are also used to diagnose epilepsy and other acute neurological conditions that CTs and MRIs are simply not designed to find.

So why are EEGs not used more often?

The size of traditional EEG systems, lack of portability and inadequate numbers of trained EEG personnel are key factors contributing to the underuse of the EEG in emergency medicine. Utilizing equipment that takes hours is not feasible in a triage situation. Brain Scientific has overcome these barriers with two separate devices: the NeuroCap(TM) and NeuroEEG(TM). Low cost, portable, small, wireless, and easy to set up, these devices make it possible for EEGs to be utilized in emergency departments across the country.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• POAI completes two separate fundraising initiatives: private placement, direct offering.
• Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively.
• Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced two funding initiatives that together total an estimated $25 million. The company has entered into securities purchase agreements with institutional and accredited investors (https://ibn.fm/WH4nw) to raise approximately $17.6 million and is involved in a direct offering that is expected to raise $7.4 million (https://ibn.fm/uSv23).

The securities purchase agreement was comprised of a total of 9,043,766 shares of common stock and warrants, offered at a purchase price of $1.95 per share. The private placement was expected to close around Feb. 22, 2021. In the announcement of the private placement, Predictive Oncology noted that it planned to use some $5.88 million of the net proceeds from the placement to pay off debt; the company has earmarked the remaining funds for general corporate purposes.

The direct offering is also between POAI and select institutional and accredited investors. Consisting of approximately 4,222,288 shares of common stock offered at a purchase price of $1.75 per share, the offering was expected to close approximately Feb. 26, 2021. The company noted that it plans to use the $7.4 million net proceeds from this placement for working capital purposes.

In the past, the pharmaceutical industry has invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics. In reality, the use of genomics alone has proven to be disappointing. Predictive Oncology is confident that a multi-omic approach offers much greater chance of success. Unfortunately, few comprehensive, multi-omic datasets exist, and such data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection – especially in cancer, an area where Predictive Oncology is focused.

POAI, however, is a leader in the nascent multi-omic game. The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer. The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes. The recently acquired funds will go far in assuring the progress of this work.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Increased nuclear power projects fueling rising demand for uranium
• UEC controls one of the largest historical uranium exploration and development databases in United States
• UEC property portfolio includes properties previously explored and developed by senior energy firms
• UEC has fully licensed, low cost, ISR projects positioned to supply the U.S. Uranium Reserve
• Nuclear energy included in Democratic Party’s energy platform for first time in 48 years

After spending a solid ten years in a downward trend, uranium stocks are now making fresh 52-week highs amid increased demand for energy (https://ibn.fm/GXF7e). Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the largest historical uranium exploration and development databases in the United States, is positioned to benefit from the trend after having acquired multiple mining sites in North and South America that allow the company to target specific uranium-rich areas.

Increased global demand for nuclear energy continues to drive the demand for uranium while long-term supplies are becoming less certain. Analyst Lyn Alden Schwartzer of Seeking Alpha predicts robust and increasing demand for uranium from developing nations and manufacturing powerhouses like China that continue to increase nuclear power consumption (https://ibn.fm/EI3BY). With lead times for new production spanning between seven to ten years or longer, current prices are not yet at levels that incentivize future production, further exacerbating longer-term supply concerns. Despite these conditions, uranium’s spot price is currently less than its production cost for most Western producers, signaling potential opportunities for suppliers and investors.

UEC controls one of the largest historical uranium exploration and development databases in the United States with properties in various locations, including Texas, New Mexico, Colorado, Arizona and Wyoming. The company’s use of historical exploration data has enabled it to target and acquire properties that have already been explored and developed by senior energy firms in the past, in some cases spending as much as $50 million to develop individual projects.

Since inception in 2005, UEC’s main strategic focus has been on acquiring and developing U.S. in-situ recovery (“ISR”) projects that are an environmentally friendly and lower-cost alternative to conventional mining. The Company has a near-term extraction profile of 4 million pounds of U3O8 per year from its south Texas and Wyoming ISR projects.

Long-term fundamentals underlying the uranium market continue to strengthen. Projections from industry analysts reveal annual deficits between production and utility requirements of about 40 million pounds well into 2026, with the gap approaching almost 70 million pounds per year by 2030.

With its fully licensed, low-cost U.S. ISR projects, UEC is also very well positioned to participate in the United States strategic uranium reserve. The uranium reserve budget is $1.5 billion over ten years for domestic uranium and conversion, with initial funding of $75 million approved by Congress for fiscal 2021. While predicted demand for uranium plays strongly into analysts’ forecasts, optimism is further bolstered by bipartisan support for nuclear energy that includes its inclusion into the Democratic Party’s energy platform for the first time in 48 years.

Uranium Energy Corp is a U.S.-based uranium mining and exploration company. In South Texas, the Company’s hub-and-spoke operations are anchored by the fully-licensed Hobson Processing Facility, which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the Company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and a large, high-grade ferro-titanium project in Paraguay. The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining.

For more information on Uranium Energy Corp., visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound
• Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44%
• CNSP has sublicensed Berubicin to WPD Pharmaceuticals in 31 countries primarily in eastern Europe and western Asia
• WPD plans to conduct a Phase 2 trial in adults with GBM and a Phase 1 trial for pediatric patients with malignant gliomas
• CNSP intends to conduct its own Phase 2, potentially pivotal, trial in s GBM patients who have failed first-line therapy and is on track to commence the study in March 2021
• Both WPD and CNSP have received favorable opinions for their respective protocols to be used in their clinical trials

The Lower Silesian Medical Chamber Ethics Committee in Wroclaw, Poland recently gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), CNS Pharmaceuticals, Inc.’s (NASDAQ: CNSP) sublicensee in Europe and Asia for Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol to be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”).

Notably, a regulatory body within a given territory – in this case, Poland – shares a positive opinion to ascertain that a study, through its protocol, respects participants’ dignity, rights, safety, and well-being.

This new development, which CNSP and WPD announced in a news release recently, set the wheels in motion for the eventual approval of WPD’s studies – a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial.

“This is an important step for WPD,” commented Mariusz Olejniczak, WPD’s CEO (https://ibn.fm/PH9lC). “From both a project and sublicense agreement point of view. After receiving the Central Ethics Committee’s positive opinion, we are planning to submit our application to the Office for Registration of Medical Products, Medical Devices, and Biocidal Products, which is the Polish equivalent of the FDA. We hope to receive an approval within three months from submission.”

WPD plans to start the Phase 2 trial in the first half of 2021 and the Phase 1 trial later in 2021. This will bring the total number of Berubicin clinical trials to be started in 2021 to three as CNSP will also conduct its Phase 2 trial. CNSP’s Phase 2 trial will evaluate the efficiency and safety of Berubicin as a treatment for adults with GBM who have failed first-line therapy.

CNSP slated its study for March= 2021, having received approval from the U.S. Food and Drug Administration (“FDA”) for its Investigational New Drug (“IND”) application and a study level Central IRB approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

“We are pleased for WPD to achieve this key milestone and are encouraged by their continued execution in furthering the development of Berubicin,” John Climaco, the CEO of CNS Pharmaceuticals, said. “We look forward to continuing our trial preparations, as well as WPD’s planned submissions to the Polish Competent Authority”.

Berubicin is CNSP’s novel anthracycline (a chemotherapy drug), which is notably unique from other anthracyclines. Historically, anthracyclines have never been used to treat primary or metastatic brain cancers because they did not have any demonstratable ability to cross the blood-brain barrier and achieve significant levels of activity in the brain. However, based on limited available data, it appears that Berubicin can cross the barrier (https://ibn.fm/JHtMJ).

Its efficacy was demonstrated in Phase 1 clinical trial completed in 2006 by Reata Pharmaceuticals, Inc. – CNSP has since acquired all the data from this trial and is currently the exclusive Berubicin license holder, subject to the sublicense agreement with WPD. The Phase 1 trial, which has 25 participants evaluable, had an overall response rate (clinical benefit of stable disease or better) of 44%. Notably, one patient’s experience with the treatment was durable as they have remained cancer-free for well over a decade through the most recent clinical evaluation on November 6, 2020. The Phase 1 trial had a limited sample size, so there can be no guarantee that similar results will be realized in the subsequent trials, but it is promising. CNSP’s Phase 2 trial will have an estimated enrollment of over 200 participants (https://ibn.fm/C6426).

CNSP is a clinical-stage biotechnology company that focuses on developing new treatments for the brain and central nervous system’s primary and metastatic cancers. Berubicin, the Company’s lead anthracycline drug candidate, is a promising treatment for glioblastoma multiforme (GBM). WPD is a biotechnology company that focuses on researching and developing medicinal products involving biological compounds and small molecules in the oncology and virology fields. WPD holds a Berubicin sublicense for the European and Asian markets.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Telehealth sector going through explosive growth; patients’ data protection remains key challenge
• Although relaxed due to COVID-19 outbreak, HIPAA guidelines protecting patients’ data security, privacy likely to tighten as pandemic abates
• RYAH appears ready to respond to strict data security requirements, uses medical data in a HIPAA-compliant setting

Telehealth is becoming increasingly popular with patients and doctors alike, but securing the integrity of patient information remains critical. As a company developing proprietary technology supporting a data-driven healthcare approach, RYAH Group appears ready to respond to the strict data security requirements.

With patients needing more access to health care, and providers and payers looking to reduce health-care costs, the use of telehealth solutions is exploding. More and more medical staff and patients alike are embracing digital healthcare options as a replacement for in-person care. Although the pandemic fuels the recent surge, the overall growth is not likely to stop once the pandemic tails off. For example, the global telemedicine market is expected to exceed $130.5 billion by 2025, with the U.S. telemedicine market expected to surpass $64.1 billion by 2025 (https://ibn.fm/AVY0p).

The technologies that power telemedicine growth are big data analytics and cloud computing. The enormous amount of data generated by devices such as smartphones, monitoring technologies, wearables and online video conferencing has opened up a world of opportunities that allows information sharing and superior analytics. Only two barriers impede the widespread adoption of big data and cloud computing in telemedicine: data privacy and security. If these critical aspects are addressed, the power of the novel technology can be harnessed to its true potential (https://ibn.fm/YRVm3).

Both patients and medical professionals are becoming accustomed to communicating through electronic devices. Although telehealth brings immense benefits, especially during the pandemic, it creates risks that must be addressed. For example, it opens up opportunities for patients’ information to fall into the wrong hands, either by accidental or malicious intent. Transmitting protected health information through unencrypted, unsecured platforms may expose protected health information.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is the U.S. legislation designed to ensure that medical providers provide data privacy and security provisions for safeguarding their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain as the pandemic subsides. Therefore, it is critical for health-care providers to use secure, HIPAA-compliant digital infrastructure to protect both themselves and patients at risk.

Unified data management is critical to ensuring that the right users have access to the right health-care data at the right time and in the right format. It allows health-care providers to have meaningful use of their data assets. Integrated data management, along with a formal data governance program, ensures data quality and trust in the data integrity.

As a company focused on the use of health devices, RYAH and its business model is founded on data and data management. RYAH leverages HIPAA-compliant medical data, fueling complex artificial intelligence algorithms to empower personalized treatment plans based on collective information.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Medical College of Georgia research shows beneficial effects from use of CBD oil to treat COVID-19 symptoms
• CBD oil found to increase apelin levels in the human body, a key peptide needed to reduce lung inflammation resulting from COVID-19
• PacRoots Cannabis specializes in developing premium quality strains, including plants with high CBD content, rare terpene contents, which could potentially be used for medicinal purposes

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) has developed a strong reputation within the global cannabis sector for producing premium quality strains and products through the employment of a meticulous, genetics-focused approach towards harvesting its crops. Following a remarkable study into the potential beneficial effects of CBD oil, the Canada-based cannabis manufacturer may potentially find itself at the forefront in the development of a remedial drug in the battle against COVID-19 (https://ibn.fm/BE8y1). Cytokine, a type of protein secreted by immune cells in response to inflammation and infection, has been found to regulate the maturation, growth, and responsiveness of particular cell populations – thereby playing an important role in the human body’s immune systems. However, an overactive cytokine response resulting from a potentially acute case of COVID-19 could also result in severe patient lung damage and, in certain cases, even lead to death. Researchers have found that a naturally occurring peptide called Apeline, which is traditionally produced in the heart, lungs, brain and blood and works as a key regulator in helping to normalize blood pressure and inflammation within the human body, may act as a suitable foil to cytokine. A recently published study carried out by scientists at the Medical College of Georgia and Dental College of Georgia (https://ibn.fm/QxEg9) found that CBD oil was shown to habitually increase apelin levels, in addition to improving blood oxygen content and reducing inflammation – and thus, the lung damage incurred through cytokine activity. In the study, scientists investigated a disease called adult respiratory distress syndrome (“ARDS”), the effects of which can result in similar lung tissue damage to that seen in severe COVID-19 cases. In the studies, blood levels of apelin were found to drop to almost zero in the midst of the disease but increased nearly twenty-fold when CBD was administered. “CBD almost brought it back to a normal level,” stated Dr Jack Yu from the Medical College of Georgia when elaborating on the effects of CBD usage on apelin levels present in the human bloodstream. While researchers were cautious on the study’s results given the need for further in-depth research into the field, it was evident that there was a strong existing correlation between ARDS and the role of apelin in reversing lung tissue damage, as well as the benefits of increasing apelin levels through CBS treatment (https://ibn.fm/IgBvn). Pac Roots Cannabis has been a pioneer within the cannabis sector in terms of improving and modifying the genetic make-up of their cannabis product, most recently through a strategic licensing agreement with Phenome Once Corp. The agreement granted Pac Roots access to one of Canada’s largest live genetic cannabis libraries with lab and field-tested, selectively bred seedlings. The Company has employed these to grow, breed and clone its own unique brands. The tie-up has enabled Pac Roots to offer its customers a remarkable portfolio of over 350 meticulously designed cultivars, including CBD-dominant plants possessing rare terpene profiles. Due to its specialty CBD plant offerings, Pac Roots appears well positioned to benefit from CBD’s positive effects on assuaging COVID-19 complications. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR